The Use of Fractional Ablative CO2 Laser vs Control on Acute Traumatic Injuries to Prevent Scar Formation
Early Intervention of Fractional Ablative CO2 Laser With or Without 830 nm LED Phototherapy for Acute Burn Injuries
1 other identifier
interventional
19
0 countries
N/A
Brief Summary
Surgical standard for treating traumatic burn injury scarring is to wait one year following the initial assault prior to beginning treatment. This study investigates the use of fractional ablative CO2 laser when begun within 3 months of a traumatic burn injury and it's impact on scar formation compared to the control. We hypothesized that early intervention would substantially mitigate the formation of scar tissue and help restore more normal appearing skin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2015
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 4, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 5, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 5, 2017
CompletedFirst Submitted
Initial submission to the registry
March 6, 2019
CompletedFirst Posted
Study publicly available on registry
March 25, 2019
CompletedMarch 25, 2019
March 1, 2019
2 years
March 6, 2019
March 22, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Manchester Scar Scale
The sum total of the Manchester Scar Scale to assess the change in scar characteristics. The scale includes the following categories: Color, matte vs shiny, contour, distortion, and texture. Scales for color, contour, distortion, and texture are rated on a 1-4 scale with 1 being most normal and 4 being most abnormal. Matte vs shiny is rated on a 1 to 2 scale with 1 being matte and 2 being shiny. Assessments completed by blinded evaluators. A decrease in score indicates improvement in scar characteristics.
From the day of the first treatment prior to intervention and at 6 months following the final treatment
Digital photography
Visual improvement as demonstrated in digital photography. Before and after photos identified by blinded evaluators
From the day of the first treatment prior to intervention and at 6 months following the final treatment
Changes in scar characteristics such as dermal and epidermal character as well as vascular structure and organization assessed through histology.
Some patients elected to do optional biopsies for deeper evaluation of changes in skin structure. Biopsies were taken prior to treatment and 6 months following treatment to assess dermal and epidermal character as well as the size and organization of vasculature. Evaluation was done qualitatively.
From the day of the first treatment prior to intervention and at 6 months following the final treatment
Secondary Outcomes (3)
Optical Coherence Tomography
From the day of the first treatment prior to intervention and at 6 months following the final treatment
Treatment Time
Treatment time was measured at each of the three treatments conducted on day 0, day 60, and day 120
Severity of post treatment cutaneous responses as evaluated by the investigator
Post treatment response was assessed immediately post treatment at each of the three treatments conducted on day 0, day 60, and day 120
Study Arms (2)
Treatment
EXPERIMENTALControl
NO INTERVENTIONInterventions
Three treatments with a fractional ablative CO2 laser 8 weeks apart
Eligibility Criteria
You may qualify if:
- Subject is between 18 and 80 years of age with burn injuries suffered within the prior 3 months
- Subject is a healthy Male or Female
- Fitzpatrick Skin Type I - IV
- Subject must have moderate - severe burn damage of sufficient bilateral area involving either the face, trunk, arms or legs
- Subject must be able to read, understand and sign the Informed Consent Form
- Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions
- Subject must be willing to have limited sun exposure for the duration of the study, including the follow-up period
- Subject is willing to have photographs taken of the treated area which will be used de-identified in evaluations and may be used de-identified in presentations and/or publications
- For female candidates - they may be post-menopausal, surgically sterilized, or using a medically acceptable form of birth control during the entire course of the study.
- Female candidates with child bearing potential - willing to take pregnancy test and result must be negative.
You may not qualify if:
- Subject is less than 18 or greater than 80 years of age.
- Subject has Fitzpatrick Skin Type V - VI
- Subject is Pregnant or planning to become pregnant during the study duration
- Subject is breast feeding during the study duration
- Subject has an active skin infection, dermatitis or a rash in the treatment area
- Subject has a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications
- Subject has a known bleeding disorder
- Subject has a known photosensitivity to the study laser wavelength, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light.
- Subject has a known collagen, vascular disease or scleroderma
- Subject has undergone any surgery or other procedures in the treatment area within 6 months of treatment which are still healing.
- Subject is suffering from significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy
- Subject is undergoing systemic chemotherapy for the treatment of cancer
- Subject has lesions suspicious for malignancy
- The systemic use of isotretinoin (Accutane®) or other retinoid derivatives within 6 months of study participation
- Any use of gold therapy for disorders such as rheumatologic disease or lupus
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Miami Dermatology and Laser Institutelead
- LUTRONIC Corporationcollaborator
Related Publications (1)
Waibel JS, Gianatasio C, Rudnick A. Randomized, Controlled Early Intervention of Dynamic Mode Fractional Ablative CO2 Laser on Acute Burn Injuries for Prevention of Pathological Scarring. Lasers Surg Med. 2020 Feb;52(2):117-124. doi: 10.1002/lsm.23170. Epub 2019 Oct 20.
PMID: 31631361DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- The treatment and control areas were randomized in advanced such that the investigator did not choose which sections to treat. Control areas were covered during the treatment so the investigator/provider could only see areas to be treated. Outcomes assessors evaluated photographs without knowledge of the identity of each area. The participant could not be masked due the experience of receiving treatment.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Owner of Miami Dermatology and Laser Institute, Board Certified Dermatologist, Director of Clinical Operations
Study Record Dates
First Submitted
March 6, 2019
First Posted
March 25, 2019
Study Start
May 4, 2015
Primary Completion
May 5, 2017
Study Completion
May 5, 2017
Last Updated
March 25, 2019
Record last verified: 2019-03
Data Sharing
- IPD Sharing
- Will not share